Insider Cluster (2 insiders) ·Filed Jun 19, 2026

PCVX

Vaxcyte, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed3mo ago
Insider cluster: 2 insiders, $542K total
Actionable Insight • Neutral

The CEO and CFO sales are immaterial in size and follow option exercises, consistent with routine tax/vesting-related selling. No bearish read-through. Monitor next quarterly results for any operational or pipeline updates that could drive sentiment.

DirectionNeutral
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
PCVX ▲ +13.63% at T+60d
NEUTRAL call ✓ call won +13.63% · α vs SPY +11.88% · entry $52.11 → $59.21
Entry anchored
Jun 18, 03:59 PM ET
via exchange tick
T+1d
-0.29%
call -0.29% · α +1.16%
$51.96
settled 3mo ago
T+5d
+8.46%
call +8.46% · α +10.53%
$56.52
settled 3mo ago
T+20d
+7.85%
call +7.85% · α +8.00%
$56.20
settled 2mo ago
T+60d
+13.63%
call +13.63% · α +11.88%
$59.21
settled 17d ago

Price Chart

Loading chart...

Executive Summary

Two top C-suite executives at Vaxcyte (CEO and CFO) sold a combined ~$542K in open-market sales on June 18, 2026, following the exercise of stock options. The sales are small relative to the $7.3B market cap (~0.007%), making them routine and likely tax-related or liquidity-driven. No material bearish signal.

Key Financial Metrics

Direction
selling
Total Value
$542.0K
Insiders
2

Key Facts

  • CEO Grant Pickering sold 225 shares for ~$11.8K on June 18
  • CFO Andrew Guggenhime sold 10,000 shares for $530K on June 18
  • Both sales followed option exercises at nominal prices ($0 and $1.79/$5.35)
  • Total open-market sales: ~$542K, or 0.007% of $7.3B market cap
  • No other insiders made open-market purchases in the window

Financial Impact

~$542K in total open-market sales, trivial relative to $7.3B market cap

insider_holdings

Risk Factors

  • No material risk from this filing; the sales are too small to signal concern

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
88% bullish (17 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-PCVX-1781827713751
13 reports for PCVX
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for PCVX — sortable, filterable
TypeNow
Aug 5, 2026
8w ago
Insider Cluster
NEUTRAL ★ 2/10
$55.92 $61.58▲ +10.12%▲ +10.72%$56.69 (+1.38%)
Jul 6, 2026
12w ago
Insider Cluster
NEUTRAL ★ 2/10
$60.67 $53.53▼ −11.77%▼ −13.10%$56.69 (−6.56%)
Jul 6, 2026
12w ago
Insider Cluster
NEUTRAL ★ 2/10
$60.67 $53.53▼ −11.77%▼ −13.10%$56.69 (−6.56%)
Jun 26, 2026
13w ago
144
NEUTRAL ★ 3/10
$57.72 $54.66▼ −5.30%▼ −5.02%$56.69 (−1.78%)
Jun 23, 2026
14w ago
8-K
NEUTRAL ★ 2/10
$53.87 $56.00▲ +3.95%▲ +2.02%$56.69 (+5.23%)
Jun 19, 2026
15w ago
Insider Cluster
NEUTRAL ★ 3/10
$52.11 $56.20▲ +7.85%▲ +8.00%$56.69 (+8.79%)
Jun 2, 2026
17w ago
Press Release
NEUTRAL ★ 4/10
$46.93 $58.39▲ +24.42%▲ +25.42%$56.69 (+20.80%)
May 6, 2026
21w ago
8-K
BEARISH ★ 7/10
$51.48 $46.93▲ +8.84%▲ +11.97%$56.69 (−10.12%)
Apr 23, 2026
23w ago
DEFA14A
NEUTRAL ★ 3/10
$59.49 $47.39▼ −20.34%▼ −24.37%$56.69 (−4.71%)
Apr 1, 2026
26w ago
Insider Cluster
NEUTRAL ★ 3/10
$58.50 $57.32▼ −2.02%▼ −11.74%$56.69 (−3.09%)
Showing 10 of 13

US Market Status

Market Open — Closes in 3h 58m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Jun 19, 2026